Hassan Javanbakht
Overview
Explore the profile of Hassan Javanbakht including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
2511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baker S, Meistermann H, Tzouros M, Baker A, Golling S, Polster J, et al.
PLoS Biol
. 2022 Dec;
20(12):e3001934.
PMID: 36542656
Viruses must balance their reliance on host cell machinery for replication while avoiding host defense. Influenza A viruses are zoonotic agents that frequently switch hosts, causing localized outbreaks with the...
2.
Allweiss L, Giersch K, Pirosu A, Volz T, Muench R, Beran R, et al.
Gut
. 2021 Jan;
71(2):372-381.
PMID: 33509930
Objective: Therapeutic strategies silencing and reducing the hepatitis B virus (HBV) reservoir, the covalently closed circular DNA (cccDNA), have the potential to cure chronic HBV infection. We aimed to investigate...
3.
Amin O, Colbeck E, Daffis S, Khan S, Ramakrishnan D, Pattabiraman D, et al.
Hepatology
. 2020 Dec;
74(1):55-71.
PMID: 33368377
Background And Aims: GS-9688 (selgantolimod) is a toll-like receptor 8 agonist in clinical development for the treatment of chronic hepatitis B (CHB). Antiviral activity of GS-9688 has previously been evaluated...
4.
Block T, Young J, Javanbakht H, Sofia M, Zhou T
Antiviral Res
. 2020 Nov;
186:104972.
PMID: 33242518
Inhibition of the host RNA polyadenylating polymerases, PAPD5 and PAPD7 (PAPD5/7), with dihydroquinolizinone, a small orally available, molecule, results in a rapid and selective degradation of hepatitis B virus (HBV)...
5.
Menne S, Wildum S, Steiner G, Suresh M, Korolowicz K, Balarezo M, et al.
Hepatol Commun
. 2020 Jun;
4(6):916-931.
PMID: 32490326
RG7834 is a small-molecule inhibitor of hepatitis B virus (HBV) gene expression that significantly reduces the levels of hepatitis B surface antigen (HBsAg) and HBV DNA in a humanized liver...
6.
Mueller H, Lopez A, Tropberger P, Wildum S, Schmaler J, Pedersen L, et al.
Hepatology
. 2018 Oct;
69(4):1398-1411.
PMID: 30365161
RG7834 is a potent, orally bioavailable small-molecule inhibitor of hepatitis B virus (HBV) gene expression that belongs to the dihydroquinolizinone (DHQ) chemical class and uniquely blocks production of both viral...
7.
Han X, Zhou C, Jiang M, Wang Y, Wang J, Cheng Z, et al.
J Med Chem
. 2018 Oct;
61(23):10619-10634.
PMID: 30286292
Chronic hepatitis B virus (HBV) infection is a serious public health burden, and current therapies cannot achieve satisfactory cure rate. There are high unmet medical needs of novel therapeutic agents...
8.
Javanbakht H, Mueller H, Walther J, Zhou X, Lopez A, Pattupara T, et al.
Mol Ther Nucleic Acids
. 2018 Jun;
11:441-454.
PMID: 29858079
Chronic hepatitis B infection (CHB) is an area of high unmet medical need. Current standard-of-care therapies only rarely lead to a functional cure, defined as durable hepatitis B surface antigen...
9.
Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, et al.
J Hepatol
. 2017 Oct;
68(3):412-420.
PMID: 29079285
Background & Aims: The hallmarks of chronic HBV infection are a high viral load (HBV DNA) and even higher levels (>100-fold in excess of virions) of non-infectious membranous particles containing...
10.
Kratochwil N, Meille C, Fowler S, Klammers F, Ekiciler A, Molitor B, et al.
AAPS J
. 2017 Jan;
19(2):534-550.
PMID: 28050713
Early prediction of human clearance is often challenging, in particular for the growing number of low-clearance compounds. Long-term in vitro models have been developed which enable sophisticated hepatic drug disposition...